QUÉBEC CITY, April 13, 2010 /PRNewswire via COMTEX News Network/ --
Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it will make an oral presentation, as well as a poster presentation on Erk/PI3K inhibitor compounds, Tuesday, April 20, at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 17-21, 2010 at the Walter E. Washington Convention Center in Washington, D.C.
Abstract # 3856
- Title: "A highly selective Erk-inhibitor with antiproliferative
efficacy and the potential for combination therapy with modulators of
the PI3K pathway", I. Seipelt, L. Blumenstein, S. Baasner, G.
Mueller, B. Aicher, M. Teifel, E. Guenther, M. Gerlach.
Oral Presentation: Session ID: Experimental and Molecular
Therapeutics 29
Tuesday, April 20, 2010, 10:30 AM - 1:00 PM
Abstract # 4474
- Title: "Dual inhibitors for PI3K and Erk induce growth inhibition of
tumor cells", I. Seipelt, M. Gerlach, S. Baasner, L. Blumenstein, G.
Mueller, B. Aicher, E. Guenther, M.l Teifel.
Poster Presentation: Session ID: Experimental and Molecular
Therapeutics 33
Location: Exhibit Hall A-C, Poster Section 24
Tuesday, April 20, 2010, 2:00 PM - 5:00 PM
Irene Seipelt, Ph.D., Associate Director, Drug Discovery & Preclinical Development at Æterna Zentaris, will make both presentations.
Copies of the abstracts are currently available and can be viewed on-line through the AACR 2010 Meeting website at: https://www.aacr.org/home/scientists/meetings--workshops/aacr-101st-annual-meeting-2010/abstracts.aspx.
About Æterna Zentaris Inc.
Æterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.